Recombinant Human CYP2D6/NADPH protein, Active

• Cat.No.: CYP2D6-363H
• Product Overview: This is a permeabilized and stabilized dried yeast powder preparation containing recombinant human CYP2D6 and recombinant human P450 NADPH oxidoreductase co expressed in the same preparation.

Specification

• Source: Pichia pastoris
• Species: Human
• Form: Lyophilized powder
• Molecular Mass: 55 Kda
• Notes: Centrifuge the vial prior to opening
• Storage: Stable for 1 year as supplied. Store dry powder at -20 centigrade. Reconstitute in 100 mM Phosphate buffer, pH 7.7. Not recommended to be stored as solution. If storing as solution, aliquot and store at -80 centigrade. Avoid repeated freeze/thaw cycles and use aliquots within one month (the human CYP2D6 will lose approximately 10% activity per week when stored at -80 centigrade). Thaw aliquots rapidly at 37 centigrade and place on ice until use (thawed aliquots should be used within 4 hours).
• Reconstitution: 100 mM Potassium Phosphate buffer, pH 7.7

Gene Information

• Gene Name: CYP2D6 cytochrome P450, family 2, subfamily D, polypeptide 6 [ Homo sapiens ]
• Official Symbol: CYP2D6
• Synonyms: CYP2D6; cytochrome P450, family 2, subfamily D, polypeptide 6; CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, cytochrome P450, family 2, subfamily D, polypeptide 7 pseudogene 2 , cytochrome P450, family 2, subfamily D, polypeptide 8 pseudogene 2 , cytochrome P450, subfamily II (debrisoquine, sparteine, etc., metabolising), polypeptide 7 pseudogene 2 , cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., metabolising), polypeptide 8 pseudogene 2 , cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., metabolizing), polypeptide 6; cytochrome P450 2D6; CPD6; CYP2D; P450 DB1; P450C2D; cytochrome P450-DB1; microsomal monooxygenase; xenobiotic monooxygenase; debrisoquine 4-hydroxylase; flavoprotein-linked monooxygenase; cytochrome P450, family 2, subfamily D, polypeptide 7 pseudogene 2; cytochrome P450, family 2, subfamily D, polypeptide 8 pseudogene 2; cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing)-like 1; cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolizing), polypeptide 6; cytochrome P450, subfamily II (debrisoquine, sparteine, etc., -metabolising), polypeptide 7 pseudogene 2; cytochrome P450, subfamily IID (debrisoquine, sparteine, etc., -metabolising), polypeptide 8 pseudogene 2; CYP2DL1; CYPIID6; P450DB1; CYP2D7AP; CYP2D7BP; CYP2D7P2; CYP2D8P2; P450-DB1; MGC120389; MGC120390
• Gene ID: 1565
• mRNA Refseq: NM_000106
• Protein Refseq: NP_000097
• MIM: 124030
• UniProt ID: P10635
• Chromosome Location: 22q13.1
• Pathway: Biological oxidations, organism-specific biosystem; Codeine and morphine metabolism, organism-specific biosystem; Cytochrome P450 - arranged by substrate type, organism-specific biosystem; Drug metabolism - cytochrome P450, organism-specific biosystem; Drug metabolism - cytochrome P450, conserved biosystem; Fatty Acid Omega Oxidation, organism-specific biosystem; Metabolism, organism-specific biosystem
• Function: aromatase activity; drug binding; electron carrier activity; heme binding; heme binding; metal ion binding; monooxygenase activity; monooxygenase activity; oxidoreductase activity; oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen

Reviews

01/26/2023

One remarkable aspect of working with the CYP2D6 protein is the excellent technical support provided by its manufacturer.

08/15/2022

The CYP2D6 protein stands out as a protein of exceptional quality, perfectly suited to meet the experimental needs of researchers.

12/09/2016

With its reliable performance and consistent results, the CYP2D6 protein provides researchers with the confidence and accuracy required for successful experimentation.

Q&As

How can knowledge of a patient's CYP2D6 genotype impact drug prescribing?

Knowing a patient's CYP2D6 genotype can help tailor drug therapy, optimizing dosage and minimizing the risk of adverse effects.

How does genetic variability impact the activity of CYP2D6?

Genetic variations can result in different CYP2D6 phenotypes, influencing an individual's ability to metabolize drugs efficiently.

Are there specific populations that exhibit higher frequencies of CYP2D6 polymorphisms?

Certain ethnic groups may have a higher prevalence of CYP2D6 polymorphisms, influencing drug response variability among different populations.

What are the clinical implications of CYP2D6 polymorphisms in drug metabolism?

CYP2D6 polymorphisms can lead to variations in drug response and efficacy, affecting the dosage and choice of medications for patients.

How can CYP2D6 testing be utilized in personalized medicine?

CYP2D6 testing can guide personalized medicine by helping clinicians choose the most appropriate medications and dosages for individual patients.